
Oncology NEWS International
- Oncology NEWS International Vol 4 No 5
- Volume 4
- Issue 5
Bristol-Myers Squibb Award Goes to Folkman
NEW YORK--Judah Folkman, MD, who first theorized that tumors form and metastasize by means of angiogenesis, is the winner of the 18th annual Bristol-Myers Squibb Award for Distinguished Achievement in Cancer Research.
NEW YORK--Judah Folkman, MD, who first theorized that tumors formand metastasize by means of angiogenesis, is the winner of the18th annual Bristol-Myers Squibb Award for Distinguished Achievementin Cancer Research.
In 1971, Dr. Folkman reported the isolation of the first angiogenicfactor, a substance that induces blood vessel growth. In 1984,he and his colleagues Yuen Shing and Michael Klagsbrun purifiedthe first tumor-derived angiogenic factor, and Dr. Folkman laterdiscovered the first angiogenesis inhibitor.
Dr. Folkman is Julia Dyckman Andrus Professor of Pediatric Surgery,Harvard Medical School, and director of the Surgical ResearchLaboratory, Children's Hospital, Boston.
The company also announced the recipients of the 1995 Bristol-MyersSquibb Unrestricted Cancer Research Grants--Indiana UniversityCancer Center and the National Cancer Institute, Milan.
Articles in this issue
about 31 years ago
Genetic Therapy Gets NIH Patentabout 31 years ago
Fusion Product Delivers Potent Toxin to Malignant Cellsabout 31 years ago
Retinoic Acid May Enhance Chemo In Ovarian Ca Cellsabout 31 years ago
Compounds Block ras Gene Function Compounds Block ras Gene Functionabout 31 years ago
Companies Merge to Form NeXstarabout 31 years ago
Antiangiogenesis Tested in Pediatric Tumorsabout 31 years ago
Delivery of Effective Cyclophosphamide Metabolite Could Reduce Toxicityabout 31 years ago
New Director Attends Office of Alternative Medicine Advisory MeetingNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Related Content



TIP137 ADELA: A Double-blind, Placebo-Controlled, Randomized Phase 3 Trial of Elacestrant + Everolimus Versus Elacestrant + Placebo in ER+/HER2- Advanced Breast Cancer (aBC) Patients With ESR1-Mutated Tumors Progressing on Endocrine Therapy (ET) + CDK4/6i

138 HER2CLIMB-05: A Randomized, Double-blind, Phase 3 Study of Tucatinib Versus Placebo Added to Trastuzumab and Pertuzumab as Maintenance Therapy for HER2+ Metastatic Breast Cancer















































